New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
17:41 EDTGALTGalectin Therapeutics reports Q2 EPS (17c), consensus (21c)
"We continued to be encouraged by the progress in our development program. We announced on July 29, the results of the second cohort of patients in our Phase 1 clinical trial for patients with NASH with advanced fibrosis which demonstrated that double the dose of GR-MD-02 that was used in the first cohort was safe and well tolerated. We also have begun recruitment and enrollment of the third cohort of the Phase 1 clinical trial, that we expect will be concluded such that results may be presented in November 2014," said Peter G. Traber, M.D., CEO, President and Chief Medical Officer, Galectin Therapeutics. "This Phase 1 first-in-man study is evaluating the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis. Additionally, we recently announced that the first patient has been dosed in cohort 1 of a Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab (Yervoy(R)) in patients with metastatic melanoma. Preclinical data have shown that GR-MD-02 holds immense potential for increasing the effectiveness of other therapies and may be an important approach in enhancing cancer immunotherapy." At June 30, the company had $34.4M of non-restricted cash and cash equivalents which it believes will be sufficient to fund currently planned future operations, research and development through mid-2016.
News For GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
09:20 EDTGALTOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTGALTGalectin Therapeutics GR-MD-02 Phase 1 trial meets primary endpoint
Subscribe for More Information
08:14 EDTGALTGalectin Therapeutics reports Q3 EPS (17c), consensus (27c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use